1. Academic Validation
  2. VEGF-A and VEGF-B Coordinate the Arteriogenesis to Repair the Infarcted Heart with Vagus Nerve Stimulation

VEGF-A and VEGF-B Coordinate the Arteriogenesis to Repair the Infarcted Heart with Vagus Nerve Stimulation

  • Cell Physiol Biochem. 2018;48(2):433-449. doi: 10.1159/000491775.
Yan-Xia Lv 1 2 Sen Zhong 1 3 Hexin Tang 1 2 Bin Luo 1 2 Shao-Juan Chen 1 4 Long Chen 1 2 Fei Zheng 1 Lei Zhang 1 Lu Wang 1 Xing-Yuan Li 1 Yu-Wen Yan 1 Ya-Mu Pan 1 Miao Jiang 1 You-En Zhang 1 Lei Wang 1 Jian-Ye Yang 1 Ling-Yun Guo 1 Shi-You Chen 5 Jia-Ning Wang 1 6 Jun-Ming Tang 1 2 6
Affiliations

Affiliations

  • 1 Institute of Clinical Medicine and Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
  • 2 Department of Physiology, School of Basic Medicine Science, Hubei University of Medicine, Shiyan, China.
  • 3 Department of Paediatrics, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
  • 4 Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • 5 Department of Physiology & Pharmacology, The University of Georgia, Athens, Georgia, USA.
  • 6 Hubei Key Lab of Embryonic Stem Cell and Institute of Biomedicine, Hubei University of Medicine, Shiyan, China.
Abstract

Background/aims: Vagus nerve stimulation (VNS) suppresses arrhythmic activity and minimizes cardiomyocyte injury. However, how VNS affects angiogenesis/arteriogenesis in infarcted hearts, is poorly understood.

Methods: Myocardial infarction (MI) was achieved by ligation of the left anterior descending coronary artery (LAD) in rats. 7 days after LAD, stainless-steel wires were looped around the left and right vagal nerve in the neck for vagus nerve stimulation (VNS). The vagal nerve was stimulated with regular pulses of 0.2ms duration at 20 Hz for 10 seconds every minute for 4 hours, and then ACh levels by ELISA in cardiac tissue and serum were evaluated for its release after VNS. Three and 14 days after VNS, Real-Time PCR, immunostaining and western blot were respectively used to determine VEGF-A/B expressions and α-SMA- and CD31-postive vessels in VNS-hearts with pretreatment of α7-nAChR blocker mecamylamine (10 mg/kg, ip) or mACh-R blocker atropine (10 mg/kg, ip) for 1 hour. The coronary function and left ventricular performance were analyzed by Langendorff system and hemodynamic parameters in VNS-hearts with pretreatment of VEGF-A/B-knockdown or VEGFR blocker AMG706. Coronary arterial endothelial cells proliferation, migration and tube formation were evaluated for angiogenesis following the stimulation of VNS in coronary arterial smooth muscle cells (VSMCs).

Results: VNS has been shown to stimulate VEGF-A and VEGF-B expressions in coronary arterial smooth muscle cells (VSMCs) and endothelial cells (ECs) with an increase of α-SMA- and CD31-postive vessel number in infarcted hearts. The VNS-induced VEGF-A/B expressions and angiogenesis were abolished by m-AChR inhibitor atropine and α7-nAChR blocker mecamylamine in vivo. Interestingly, knockdown of VEGF-A by shRNA mainly reduced VNS-mediated formation of CD31+ microvessels. In contrast, knockdown of VEGF-B powerfully abrogated VNS-induced formation of α-SMA+ vessels. Consistently, VNS-induced VEGF-A showed a greater effect on EC tube formation as compared to VNS-induced VEGF-B. Moreover, VEGF-A promoted EC proliferation and VSMC migration while VEGF-B induced VSMC proliferation and EC migration in vitro. Mechanistically, vagal neurotransmitter acetylcholine stimulated VEGF-A/B expressions through m/nACh-R/PI3K/Akt/Sp1 pathway in EC. Functionally, VNS improved the coronary function and left ventricular performance. However, blockade of VEGF receptor by antagonist AMG706 or knockdown of VEGF-A or VEGF-B by shRNA significantly diminished the beneficial effects of VNS on ventricular performance.

Conclusion: VNS promoted angiogenesis/arteriogenesis to repair the infracted heart through the synergistic effects of VEGF-A and VEGF-B.

Keywords

Angiogenesis; Myocardial infarction; VEGF-A; VEGF-B; Vagal nerve stimulation.

Figures
Products